

Resource Summary Report

Generated by [dkNET](#) on Sep 1, 2026

JIMT-1

RRID:CVCL_2077

Type: Cell Line

Proper Citation

RRID:CVCL_2077

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_2077

Proper Citation: RRID:CVCL_2077

Description: Cell line JIMT-1 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Female

Disease: Breast ductal carcinoma

Defining Citation: [PMID:15634652](#), [PMID:17334996](#), [PMID:20215515](#), [PMID:22460905](#), [PMID:24176112](#), [PMID:25485619](#), [PMID:25877200](#), [PMID:25960936](#), [PMID:26055192](#), [PMID:26589293](#), [PMID:27397505](#), [PMID:28196595](#), [PMID:30894373](#), [PMID:30971826](#), [PMID:31068700](#), [PMID:31978347](#), [PMID:35839778](#)

Comments: Characteristics: ER-negative. Has amplified ERBB2 and is insensitive to trastuzumab (Herceptin) (PubMed=15634652)., Population: Caucasian., Part of: MD Anderson Cell Lines Project., Part of: JWGray breast cancer cell line panel., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: JIMT-1

Synonyms: JIMT1, JIMT

Cross References: BTO:BTO_0004312, CLO:CLO_0009912, EFO:EFO_0005388, AddexBio:C0006005/50, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, BioGRID_ORCS_Cell_line:627, BioSample:SAMN03473040, BioSample:SAMN10989571, cancercellines:CVCL_2077,

Cell_Model_Passport:SIDM01037, ChEMBL-Cells:CHEMBL4295430, ChEMBL-Targets:CHEMBL4296443, CLS:305433, Cosmic:1348959, Cosmic:2165010, Cosmic-CLP:1298157, DepMap:ACH-000711, DSMZ:ACC-589, DSMZCellDive:ACC-589, EGA:EGAS00001000610, EGA:EGAS00001000978, EGA:EGAS00001002554, GDSC:1298157, GEO:GSM155212, GEO:GSM274696, GEO:GSM274707, GEO:GSM783975, GEO:GSM827173, GEO:GSM847393, GEO:GSM847489, GEO:GSM887183, GEO:GSM888256, GEO:GSM1172878, GEO:GSM1172971, GEO:GSM1374578, IARC_TP53:28224, LiGeA:CCLE_176, LINCS_HMS:51118, LINCS_LDP:LCL-1482, PharmacDB:JIMT1_702_2019, PRIDE:PXD000691, PRIDE:PXD030304, Progenetix:CVCL_2077, PubChem_Cell_line:CVCL_2077, SLKBase:3562, Ubigene:YC-C046, Wikidata:Q54898927

ID: CVCL_2077

Record Creation Time: 20220427T220650+0000

Record Last Update: 20260829T234346+0000

Ratings and Alerts

No rating or validation information has been found for JIMT-1.

No alerts have been found for JIMT-1.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 194 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Yang DM, et al. (2026) Isolation, Structural Elucidation, and Biological Evaluation of Homoisoflavonoids From Pterolobium Macropterum. Chemistry & biodiversity, 23(4), e71207.

El Sahili A, et al. (2026) Antibody-drug-conjugates prepared with Peptide Asparaginyl Ligases achieve strong in vitro and in vivo anti-tumor activity. Molecular cancer therapeutics.

Pougoue Ketchemen J, et al. (2026) Potency and safety of novel [225Ac]Ac-labeled pertuzumab-PEGylated emtansine drug conjugate against HER2-positive breast cancer. British journal of cancer, 134(12), 1820.

Yamaguchi A, et al. (2026) Affinity-optimized TROP2 antibodies support potent antitumor activity in antibody-drug conjugates. Antibody therapeutics, 9(2), 127.

Stamati I, et al. (2025) Anti-HER2, High-DAR Antibody Fragment-Drug Conjugates with a Glucuronide-Based MMAE Linker-Payload Demonstrate Superior Efficacy over IgG-Based ADCs. *Molecular cancer therapeutics*, 24(9), 1295.

Hosking MP, et al. (2025) Preferential tumor targeting of HER2 by iPSC-derived CAR T cells engineered to overcome multiple barriers to solid tumor efficacy. *Cell stem cell*, 32(7), 1087.

Lin H, et al. (2025) Characterization and comparative analysis of multifunctional natural killer cell engagers during antitumor responses. *Cell reports. Medicine*, 6(5), 102117.

Yassin AA, et al. (2025) Enhancing the Efficacy of CAR-T Cell Production Using BX795 and Rosuvastatin in a Serum-Free Medium. *International journal of molecular sciences*, 26(7).

Bednova O, et al. (2025) Integrating Biochemical and Computational Approaches Reveal Structural Insights in Trastuzumab scFv-Fc Antibody Engineering. *Biomolecules*, 15(5).

Rask G, et al. (2025) Stromal collagen IV expression and risk of breast cancer death in ductal carcinoma in situ. *BJC reports*, 3(1), 73.

Zhou RW, et al. (2025) Safe immunosuppression-resistant pan-cancer immunotherapeutics by velcro-like density-dependent targeting of tumor-associated carbohydrate antigens. *Cell*.

Zähringer A, et al. (2025) Alstain: Enhancing microglial phagocytosis analysis through deep learning. *Cell reports methods*, 5(11), 101207.

Yamaguchi A, et al. (2025) ¹⁷⁷Lu-Labeled Antibody-Drug Conjugate: A Dual-Mechanistic Treatment Modality in Solid Tumors. *Molecular cancer therapeutics*, 24(6), 907.

Palhares LCGF, et al. (2025) An IgE antibody targeting HER2 identified by clonal selection restricts breast cancer growth via immune-stimulating activities. *Journal of experimental & clinical cancer research : CR*, 44(1), 49.

Dodson AE, et al. (2024) Pan-Cancer Analysis of Homologous Recombination Deficiency in Cell Lines. *Cancer research communications*, 4(12), 3084.

Vinik Y, et al. (2024) Computational pipeline predicting cell death suppressors as targets for cancer therapy. *iScience*, 27(9), 110859.

Pougoue Ketchemen J, et al. (2024) Effectiveness of [⁶⁷Cu]Cu-trastuzumab as a theranostic against HER2-positive breast cancer. *European journal of nuclear medicine and molecular imaging*.

Petersen ME, et al. (2024) Design and Evaluation of ZD06519, a Novel Camptothecin Payload for Antibody Drug Conjugates. *Molecular cancer therapeutics*, 23(5), 606.

Hofman DA, et al. (2024) Translation of non-canonical open reading frames as a cancer cell survival mechanism in childhood medulloblastoma. *Molecular cell*, 84(2), 261.

Peng H, et al. (2024) Define Critical Parameters of Trastuzumab-Mediated ADCC Assays via Assay Optimization Processes, Focusing on the Impact of Cryopreserved Effector

Cells on Assay Performance. Cancers, 16(13).